The VJSessions bring together leading international experts for in-depth discussions on advances and debated topics across neurological diseases, including stroke, multiple sclerosis, movement disorders, and more.
Stroke Sessions
13 Apr 2026
Life after stroke: First steps in secondary stroke prevention
06 Feb 2026
Should incidentally discovered covert brain infarcts be treated with aspirin and statins?
26 Nov 2025
Interim results from the PHOTONIC study: prehospital video triage for suspected stroke
26 Nov 2025
Vocational rehabilitation for stroke: insights from a speech and language and occupational therapist
22 Oct 2025
Surf therapy for stroke in the chronic phase of rehabilitation: insights from a surf clinic
06 Apr 2025
Blood pressure targets in ICH: should we go low?
07 Feb 2025
Wrap-up of ISC 2025 with the Chair and Vice Chair
07 Feb 2025
Major unmet needs in the treatment of stroke
04 Feb 2025
Trials investigating medium and distal vessel occlusions and other meeting highlights
04 Jan 2025
Endovascular therapy in medium vessel occlusion stroke: findings from the DISTAL trial
31 Aug 2023
ENRICH trial: early surgical intervention in intracerebral hemorrhage
21 Feb 2022
ESO-ESMINT expedited recommendation on IVT before MT in acute ischemic stroke
13 Feb 2022
ESO guidelines on MSUs for prehospital stroke management
Multiple Sclerosis Sessions
28 Jun 2026
A discussion at EAN 2026 on the impact of climate change on neurological diseases
16 Apr 2024
Distinguishing true relapses from pseudo-relapses in MS: the impact on clinical trial readouts
23 Mar 2024
AssistMS: testing the value of an AI tool for MRI scan interpretation in clinical practice
23 Mar 2024
AttackMS and ChariotMS: optimizing care from diagnosis to advanced disease
23 Mar 2024
Challenges in MS care: feedback gaps and cost-saving missteps
12 Oct 2023
The next steps for tolebrutinib in MS
12 Oct 2023
Baseline characteristics in the HERCULES trial: tolebrutinib in non-relapsing SPMS
12 Oct 2023
Navigating the treatment landscape in MS: the potential of BTK inhibitors
12 Oct 2023
The potential role of BTK inhibitors in addressing MS treatment gaps
12 Oct 2023
Positive Phase II data of novel anti-CD40L antibody frexalimab in MS
12 Oct 2023
Exploring new treatment avenues in MS and beyond
Movement Disorders Sessions
28 Jun 2026
A discussion at EAN 2026 on the impact of climate change on neurological diseases
16 Sep 2022
Improving CNS delivery and distribution of Huntington's disease therapies
16 Sep 2022
